Ruiyuan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruiyuan Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Chunmei Wen
School of Medicine, Anhui University of Science & Technology
2 shared publications- Huihui Tao
School of medicine, Anhui University of Science & Technology, Huainan, China
2 shared publications Jingquan He
Department of Radiotherapy, Shenzhen Traditional Chinese Medicine Hospital
2 shared publicationsMengyao Wu
School of Medicine, Anhui University of Science & Technology
2 shared publications- Mingquan Guo
School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, China
2 shared publications - Qingwen Wang
Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China
2 shared publications
Latest Publications
- 26 September 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-13
Association of late bedtime and glycemic control with diabetic retinopathy in adults with diabetes: a population-based study
1. Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes and remains a leading cause of vision loss among people with diabetes (Cheung et al. 2010; Yau et al. 2012). After ...
- 26 September 2026
- Published by Taylor & Francis in Biological Rhythm Research
- p. 1-13
Association of late bedtime and glycemic control with diabetic retinopathy in adults with diabetes: a population-based study
1. Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes and remains a leading cause of vision loss among people with diabetes (Cheung et al. 2010; Yau et al. 2012). After ...
- 17 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e69038
Cholesterol and Stearamide Mediate Lymphocyte Apoptosis and Cytokine Secretion in Systemic Lupus Erythematosus
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.
- 17 October 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 224,p. e69038
Cholesterol and Stearamide Mediate Lymphocyte Apoptosis and Cytokine Secretion in Systemic Lupus Erythematosus
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.
- 17 October 2025
- Published by MyJove Corporation
- No. 224,p. e69038
JoVE Video Dataset
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.
- 17 October 2025
- Published by MyJove Corporation
- No. 224,p. e69038
JoVE Video Dataset
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.